04th week of 2016 patent applcation highlights part 10 |
Patent application number | Title | Published |
20160022719 | COMPOSITION FOR BUFFERED AMINOALKYL GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND ITS USE FOR ENHANCING AN IMMUNE RESPONSE - There is provided a composition comprising an aminoalkyl glucosaminide phosphate compound or a pharmaceutically salt thereof and a buffer for use as an immunomodulator. | 2016-01-28 |
20160022720 | COMPOSITIONS AND METHODS FOR TREATING DISEASE STATES ASSOCIATED WITH ACTIVATED T CELLS AND/OR B CELLS - Disclosed are combination therapies and related compositions that may contain one or more of a p53 potentiating agent, a DNA-damaging agent, an agent that inhibits cell cycle check point, and a pharmaceutically acceptable carrier. Also disclosed are methods of using such compositions for the treatment of conditions related to T cell and/or B cell activation in subjects in need of such treatment. | 2016-01-28 |
20160022721 | ETOPOSIDE AND PRODRUGS THEREOF FOR USE IN TARGETING CANCER STEM CELLS - The present invention pertains to the use of podophyllotox in derivatives, such as CAP7.1, in methods for inhibition of and/or prevention of the growth and/or survival of cancer stem cells. The invention discloses the surprisingly specific activity of the compounds in accordance with the invention against a cancer stem cell population. In this respect the present invention provides the use of the compounds as described in the treatment of cancer, specifically of cancers which have a high risk of developing metastases, chemotherapeutic resistances and/or cancer relapse. Provided are novel methods of cancer treatment, and pharmaceutical compositions comprising the compounds as described, for use in such treatment methods. | 2016-01-28 |
20160022722 | METHODS AND MATERIALS FOR REDUCING THE RISK OF INFECTIONS - This document relates to methods and materials for reducing the risk of infection after a shoulder surgery or medical procedure. For example, this document relates to methods and materials for using a topical composition containing clindamycin or erythromycin to reduce the risk of or to prevent infection associated with shoulder surgeries or medical procedures. | 2016-01-28 |
20160022723 | COMBINATION THERAPY FOR THE TREATMENT OF PROLIFERATIVE DISEASES - A method of treating a proliferative disease, such as cancer, is disclosed. The method comprises administering to a mammal in need thereof synergistically therapeutically effective amounts of: (i) (2R,3S)—N-((3S)-1-methyl-2-oxo-5-phenyl-2,3-di-hydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide; (ii) 2-deoxy-2,2-difluorocytidine monohydrochloride (beta-isomer); and (iii) optionally, one or more additional anticancer agents. | 2016-01-28 |
20160022724 | METHODS FOR TREATING PARAMYXOVIRUSES - Described herein are methods for treating and/or ameliorating a paramyxovirus infection that include using compound (A), or a pharmaceutically acceptable salt thereof. | 2016-01-28 |
20160022725 | INJECTABLE FORMULATIONS FOR TREATING CANCER - The present invention provides injectable formulations of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders. | 2016-01-28 |
20160022726 | VITAMIN B12 NASAL SPRAY AND METHOD OF USE - The present invention relates generally to vitamin B | 2016-01-28 |
20160022727 | IMMUNOMODULATING COMPOUNDS AND RELATED COMPOSITIONS AND METHODS - Provided herein are compounds, compositions and methods for balancing a T-helper cell profile and in particular Th1, Th2, Th17 and Treg cell profiles, and related methods and compositions for treating or preventing an inflammatory condition associated with an imbalance of a T-helper cell profile. | 2016-01-28 |
20160022728 | miRNA FOR TREATING CANCER AND FOR USE WITH ADOPTIVE IMMUNOTHERAPIES - In some aspects, miRNA for the treatment of cancer are provided. In some embodiments, a miRNA (e.g., miR-124, miR-142, and/or miR-138) may be used to promote or enhance immune destruction of a cancer, or reduce the immune suppression of the cancer, in a subject. In other aspects, the miRNA may be used in, or in combination with, an adoptive immunotherapy. | 2016-01-28 |
20160022729 | Compounds to Modulate Intestinal Absorption of Nutrients - This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compounds for treating disorders requiring a modulation of certain nutrients to the body including diabetes type II and clinical obesity. | 2016-01-28 |
20160022730 | COMPOSITIONS AND METHODS OF USE FOR WOUND HEALING - Described herein are a solution, composition, and kit of poly (acetyl, arginyl) glucosamine (PAAG), methods of making the solution, and method of treating wounds with the solution, the method comprising administering to a subject an effective amount of a solution comprising PAAG, wherein the PAAG when administered topically contacts the wound, thereby treating the wound. | 2016-01-28 |
20160022731 | INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES - A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters. | 2016-01-28 |
20160022732 | DISSOLUTION STABILITY OF CALCIUM CARBONATE TABLETS - The present invention relates to a method for the preparation of a tablet comprising at least 50% w/w of calcium carbonate, the method comprising
| 2016-01-28 |
20160022733 | NOVEL FORMULA OF IRON BASED NANOCOMPOSITES FOR RAPID AND EFFICIENT TREATMENT OF IRON DEFICIENCY ANEMIA - New formulas of Iron oxides nanoparticles capped with a mixture of multivitamins such as folic acid, Nicotinic acid (vitamin B9) and Ascorbic acid (vitamin C) has been developed for the rapid and efficient treatment of life threatening iron-deficiency anemia. Small single dose of iron oxides-multivitamin nano-composite as low as 8.3 mg elemental iron per does is sufficient to increase the hemoglobin level from 4.4 g/dl up to 14.6 g/dl within only four days after administration. The multivitamin which used in this nano-composite enhances iron absorption significantly and elevated the concentration of hemoglobin. Two dosage forms of Iron nano-composites have been developed, gel capsules and aqueous solution for oral administration. Animal trials studies reveal that introducing single dose of Iron Oxide-vitamin nano-composites containing 8.6 mg elemental iron per kg rat body weight is sufficient to correct the hemoglobin level and cure Anemia via oral administration. | 2016-01-28 |
20160022734 | NUTRITIONAL SUPPLEMENT FOR GROWTH ENHANCEMENT - Provided are nutritional supplements designed for enhancing the growth, particularly the linear growth, of pre-pubertal children with a stature measure short compared to the norm. The nutritional composition includes an energy source, arginine and a combination of micronutrients. | 2016-01-28 |
20160022735 | Methods and Compositions for Promoting Wound Healing - The present invention provides methods and compositions that use the combination of Tris and EDTA to inhibit the growth of microorganisms at the site of a wound or burn, and/or to promote the healing of a wound or burn, and/or to reduce the sensation of pain at the site of a wound or burn. The amount of Tris and EDTA applied to a wound or burn can be selected to achieve one or more of the foregoing effects. | 2016-01-28 |
20160022736 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF - Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells. | 2016-01-28 |
20160022737 | GENE EDITING FOR HIV GENE THERAPY - The present disclosure is in the field of genome engineering, particularly targeted integration of anti-HIV transgenes into the genome of a cell for the treatment and/or prevention of HIV. | 2016-01-28 |
20160022738 | METHODS FOR CELL EXPANSION AND USES OF CELLS AND CONDITIONED MEDIA PRODUCED THEREBY FOR THERAPY - A method of cell expansion is provided. The method comprising culturing adherent cells from placenta or adipose tissue under three-dimensional culturing conditions, which support cell expansion. | 2016-01-28 |
20160022739 | CLOSED SYSTEM SEPARATION OF ADHERENT BONE MARROW STEM CELLS FOR REGENERATIVE MEDICINE APPLICATIONS - A method for isolating and processing bone marrow derived stem cells, including the steps of: (a) collecting a biological sample containing adherent bone marrow stem cells in a receptacle with interior walls coated with a cell-adherent substrate; (b) incubating the bone marrow cells on the adherent substrate so that a layer of adherent bone marrow stem cells adheres to the substrate; (c) washing any non-adherent cells from the substrate; and (d) collecting the bone marrow stem cell layer. Isolation kits and use of bone marrow cells harvested for cell therapies are also described. | 2016-01-28 |
20160022740 | Minced Cartilage Systems and Methods - Compositions comprising a plurality of cartilage particles from a human adult cadaveric donor, wherein the cartilage particles comprise viable chondrocytes, and a biocompatible carrier are provided. Methods of manufacturing cartilage compositions comprising a plurality of cartilage particles from a human adult cadaveric donor are also provided. | 2016-01-28 |
20160022741 | CAMELID COMPOUND(S), COMPOSITION(S) AND METHOD(S) - Described herein are compounds, compositions and methods for the treatment of a subject having cancer, skin conditions, blood flow and/or growth failure. In one aspect of the present invention, there is provided compositions and methods for treating a subject having cancer, skin conditions, blood flow and/or growth failure, comprising fat derived from a camel. There are also described sunscreen and photoprotective compounds, compositions and methods, comprising fat derived from a camel. | 2016-01-28 |
20160022742 | MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE - The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient. | 2016-01-28 |
20160022743 | HUMAN VERY SMALL EMBRYONIC-LIKE (VSEL) STEM CELLS FOR TREATMENT OF OCULAR DISEASE - The present invention relates to use of very small embryonic-like (VSEL) stem cells in therapies for ocular disease involving retinal degeneration or dysfunction. The invention also included pharmaceutical compositions made with VSELs which may be used to restore lost vision or reduce or halt vision loss due to diseases or disorders of the retina, or other diseases or retinal injuries that would benefit from stem cell replacement therapy. | 2016-01-28 |
20160022744 | Method Of Using Mitotically Inactivated Stem Cells For Damaged Tissue Repair - The present invention is directed to the use of mitotically and/or lethally inactivated stem cells for the repair of damaged organs and/or tissues. Stem cells are mitotically and/or lethally inactivated and transplanted into damaged tissue. Any form of ex vivo inactivation of stem cells may be used such that the stem cells cannot undergo mitosis or cell division before in vivo application. Mitotically and/or lethally inactivated stem may be used to ameliorate numerous disease, injury, traumatic, ischemic, aging, and/or degenerative conditions in different types of organs and/or tissues. | 2016-01-28 |
20160022745 | BUTYROGENIC BACTERIA AS PROBIOTICS TO TREAT CLOSTRIDIUM DIFFICILE - The subject invention pertains to the use of certain bacterial strains, particularly butyrogenic bacteria, for preparing a composition to treat and/or prevent | 2016-01-28 |
20160022746 | METHODS AND GROUPS - A method, for the identification of bacterial isolates suitable for use in bacteriotherapy, the method comprising: (i) preparing a suspension of material collected from a host harbouring microbiota; (ii) addition of an activator of bacterial spores sufficient to allow growth of bacteria from spores present in the suspension; (iii) culturing the suspension; and (iv) identification of at least one bacterial species within the culture. | 2016-01-28 |
20160022747 | Antibacterial Phage, Phage Peptides and Methods of Use Thereof - The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies. | 2016-01-28 |
20160022748 | Recombinant VSV for the Treatment of Tumor Cells - The present invention relates to compositions and methods for the treatment of tumor and/or malignant and/or cancerous cells. The present invention provides VSV vectors comprising nucleic acid encoding a cytokine, such as interleukin or interferon, or a suicide gene, such as thymidine kinase, or other biological protein, such as heat shock protein gp96, or endostatin or angiostatin, wherein said VSV vectors exhibit greater oncolytic activity against the tumor and/or malignant and/or cancerous cell than a wild-type VSV vector. The present invention also provides methods of making such vectors, host cells, expression systems, and compositions comprising such VSV vectors, and viral particles comprising such VSV vectors. The present invention also provides methods for producing oncolytic activity in a tumor and/or malignant and/or cancerous cell comprising contacting said cell with a VSV vector of the present invention. The present invention also provides methods for suppressing tumor growth comprising contacting said tumor with a VSV vector of the present invention. The present invention also provides methods for eliciting an immune response to a tumor cell in an individual. | 2016-01-28 |
20160022749 | METHOD OF IMPROVING HEMATOLOGICAL PARAMETERS AND BRAIN DYSFUNCTION WITH GANODERMA TSUGAE EXTRACT - The invention relates to a method of improving hematological parameters and brain dysfunction by administrating an extract of | 2016-01-28 |
20160022750 | POMEGRANATE FRUIT POLYPHENOL COMPOSITION AND METHODS OF USE AND MANUFACTURE THEREOF - A pharmaceutical composition with an active pharmaceutical ingredient including a pomegranate fruit polyphenol extract. The pomegranate fruit polyphenol extract includes at least about 3% combined punicalagin A and punicalagin B by weight, less than about 5% ellagic acid and their derivatives by weight, and less than about 1% anthocyanins by weight. | 2016-01-28 |
20160022751 | NOVEL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND IMPROVING COGNITIVE FUNCTION OF ALZHEIMER'S PATIENTS - The present invention relates to a pharmaceutical composition for treating Alzheimer's disease and improving cognitive function of Alzheimer's patients, and more specifically for pharmaceutical composition for treating Alzheimer's disease and improving cognitive function of Alzheimer's patients comprising ginsenoside complex prepared by sequential fraction of steam-dried unripened ginseng berries using solvents and used thereof. | 2016-01-28 |
20160022752 | PLANT EXTRACTS WITH ANTI-DIABETIC AND OTHER USEFUL ACTIVITIES - This invention relates to plant extracts containing nutritionally beneficial or medicinally active compounds. Some of these extracts, or the purified compounds contained therein, may be used for the nutritional support, prevention, treatment, or possible cure of various metabolic and other diseases and disorders in human beings and animals, including type 1 and type 2 diabetes, by regulating insulin signaling. This regulatory effect may include modulations of the levels and/or activity of the Insulin Receptor (IR), the Insulin-like Growth Factor (IGF) Receptor, and/or the Insulin Receptor Substrate (IRS) proteins in cells and tissues in the body. | 2016-01-28 |
20160022753 | COMPOSITIONS DERIVED FROM SWEET POTATO GREENS AND METHODS OF PREPARATION AND USE - The present invention includes methods of identifying a fraction of a sweet potato greens extract (SPGE) that is useful in reducing the risk of or treating, cancer, hypertension, diabetes, or a wound; compositions including the identified fraction(s); methods of administering SPGEs or fractions thereof; and uses of the compositions described herein in the preparation of a medicament. | 2016-01-28 |
20160022754 | Supplement Composition and Methods of Use - The present disclosure provides a supplement composition for an animal comprising: cranberry oil in the volume range of 10-30%, 20-40% soybean oil in the volume range of and fish oil in the volume range of 30-70%. | 2016-01-28 |
20160022755 | HERBAL GEL FROM CHESTNUT SEED COAT FOR PELVIC FLOOR MUSCLE RELAXATION IN WOMEN AND A METHOD OF SYNTHESIZING THE SAME - The embodiments herein disclose a method for extracting the herbal extract from acorn or oak nut of | 2016-01-28 |
20160022756 | METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS OF RHIZOMES FROM ALPINIA GALANGA OR ALPINIA CONCHIGERA HAVING A HIGH CONTENT OF 1'S-1'-ACETOXYCHAVICOL ACETATE (ACA) - The present invention relates to a method for preparing a granulate composition of rhizomes from | 2016-01-28 |
20160022757 | THERAPEUTIC METHODS FOR TREATING SOLID TUMORS AND RELATED DIAGNOSTIC METHODS - The present invention provides a method for treating a subject afflicted with a cancer which comprises administering to the subject (i) a proteasome antagonist and (ii) a PI3K signal transduction pathway antagonist, each of (i) and (ii) in an amount such that when both (i) and (ii) are administered, the administration is effective to treat the subject. The present invention also provides a method for treating a subject afflicted with a cancer which comprises administering to the subject (i) a proteasome antagonist, and (ii) an oligonucleotide which decreases the amount of PI3K, mTor, TORC1, TORC2, AKT, or JNK produced by cells of the cancer. The present invention provides processes for identifying whether a compound is an epithelial cancer drug candidate. The present invention also provides a method for identifying a cancer patient who will likely benefit from treatment with a PI3K signal transduction pathway antagonist. | 2016-01-28 |
20160022758 | AGENT DERIVED FROM TORTOISE SPLEEN STIMULATING MAMMALIAN HEMOPOIESIS - The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them. | 2016-01-28 |
20160022759 | Methods for Increasing the Selective Efficacy of Gene Therapy Using CAR Peptide and Heparan-Sulfate Mediated Macropinocytosis - Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, PAH, inflammation, diabetes, Crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome. The compositions can also serve as a receptor for disease selective cell penetrating peptides in the cells and extracellular matrix of diseased tissues. | 2016-01-28 |
20160022760 | METHODS OF TREATING CELIAC DISEASE WITH LARAZOTIDE - The present invention provides compositions comprising Larazotide. The invention further provides methods of using the Larazotide compositions for treating celiac disease in symptomatic celiac disease patients. | 2016-01-28 |
20160022761 | DEREPRESSION OF IMMUNITY IN ONCOLOGICAL AND VIROLOGICAL CONDITIONS BY HIGH MOBILITY GROUP BOX 1 DERIVED PEPTIDES - Disclosed are compositions of peptides derived from the High Mobility Group Box 1 (HMGB1) protein that are useful in suppressing inhibitory activity of T regulatory cells in conditions of cancer and virus infections. Specifically, this application provides means of derepressing immunity in a state of immune suppression through significantly decreasing the number and/or activity of T regulatory cells. | 2016-01-28 |
20160022762 | Agent for Eliminating Multidrug Resistance - The invention belongs to medicine, namely to pharmacology, and may be used to overcome multiple drug resistance in oncological and infectious patients undergoing long-term chemotherapy. Essence of the invention: proposed herein as a therapeutic agent intended to overcome multiple drug resistance is a hexapeptide with the following structural formula: lysyl-histidyl-glycyl-lysyl-histidyl-glycine. | 2016-01-28 |
20160022763 | COMPOSITIONS AND METHODS FOR INHIBITING CELLULAR ADHESION OR DIRECTING DIAGNOSTIC OR THERAPEUTIC AGENTS TO RGD BINDING SITES - Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH | 2016-01-28 |
20160022764 | PHARMACEUTICAL COMPOSITIONS - The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex. | 2016-01-28 |
20160022765 | Cyclosporin Analogs - Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions. | 2016-01-28 |
20160022766 | mTOR Ligands and Polynucleotides Encoding mTOR Ligands - The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate mTOR activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands and polyligands to a cellular localization signal, epitope tag and/or a reporter. The invention also includes polynucleotides encoding the ligands and polyligands. | 2016-01-28 |
20160022767 | PROTEIN PARTICLES COMPRISING DISULFIDE CROSSLINKERS AND USES - This disclosure relates to particles comprising recombinant proteins, pharmaceutical composition comprising the particles, and therapeutic uses related thereto. In certain embodiments, the particles are made by the process of producing recombinant proteins and conjugating the recombinant proteins to form nanoparticles with a linking reagent comprising disulfide bonds. Typically the recombinant protein has a polypeptide of viral, fungal, or bacterial origin such as secreted effector proteins AvrA and YopJ. In certain embodiments, the disclosure relates to treating or preventing autoimmune diseases, cancer, or inflammatory diseases, or conditions such as inflammatory bowel disease (IBD). | 2016-01-28 |
20160022768 | RECONSTITUTED HIGH DENSITY LIPOPROTEIN FORMULATION AND PRODUCTION METHOD THEREOF - A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction. | 2016-01-28 |
20160022769 | COMPOSTIONS AND METHODS FOR TREATING RETINAL DISEASE - The invention provides methods, compositions, and kits featuring Wnt signaling enhancing compounds for use in preventing or treating retinal disease. | 2016-01-28 |
20160022770 | USE OF GLYCOMACROPEPTIDE TO IMPROVE WOMEN'S HEALTH - Methods for improving the health of a female human or non-human animal are disclosed. The methods include the step of administering to the animal compositions including an effective amount of glycomacropeptide (GMP) for effectuating the methods. Specifically, the methods can be used to increase the rate of fat metabolism or fat oxidation, decrease percentage of body fat, increase the rate of bone mineralization, increase bone mineral content, increase bone mineral density, and/or increase bone strength in the animal. | 2016-01-28 |
20160022771 | SENSATION-IMPROVING AGENT - An object of the present invention is to provide a safety sensation-improving agent that can improve dulled peripheral sensations through daily ingestion or application to the skin. Another object of the present invention is to provide a sensation-improving food, beverage, feed, or cosmetics that can improve dulled peripheral sensations through oral ingestion or application to the skin. A sensation-improving agent containing a milk-derived protein and/or a hydrolysate therefrom as an active ingredient is provided. The milk-derived protein and/or the hydrolysate therefrom can be orally ingested or applied direct to the skin to improve dulled sensations, particularly peripheral sensations, and be formed into a sensation-improving food, beverage, feed, or cosmetics. | 2016-01-28 |
20160022772 | Cytokine Receptors as Targets for Hypertension Therapy and Methods of Use - The present disclosure provides methods of treating or ameliorating hypertension in a subject comprising administering a therapeutically effective amount of an IL-1 receptor antagonist. | 2016-01-28 |
20160022773 | METHODS FOR PROMOTING WOUND HEALING AND HAIR GROWTH - The present invention generally relates to uses of glial cell line-derived growth factor (GDNF) in cutaneous wound healing and hair growth. Methods of effecting hair growth and/or wound healing which feature administration of GDNF, or a biologically active fragment thereof, to subjects, e.g., human subject, are disclosed herein. The invention relates also to formulations and kits for achieving the indicated pharmaceutical advantages. | 2016-01-28 |
20160022774 | DIAGNOSIS AND TREATMENT OF FIBROSIS - The invention relates to the treatment of fibrosis using modified mRNA molecules. | 2016-01-28 |
20160022775 | TREATING LYSOSOMAL STORAGE DISEASE - Provided herein are compositions, kits and methods related to the treatment of one or more lysosomal storage diseases (LSDs) in a subject and methods of identifying agents that are useful for the treatment of one or more LSDs. The compositions, kits, and methods are based on the novel discovery that agents effective for treating LSD must have two characteristics: they must inhibit cell death and reduce suppression of cell division caused by toxic substances that accumulate in LSD. Exemplary agents include polypeptides (e.g., IGF-1, VEGF) and small molecules (e.g., chlorotrianisene, clofoctal, colforsin, and tulobuterol). | 2016-01-28 |
20160022776 | TRAIL RECEPTOR AGONISTS FOR TREATMENT OF FIBROTIC DISEASE - Pro-apoptotic agents such as ligands and agonists of agonistic TRAIL receptors can induce or increase apoptosis of cells that cause fibrosis and underlying diseases such as liver, pancreatic, lung and skin diseases characterized by fibrosis, cirrhosis, or complications thereof. The compositions and methods can be used to selectively remove activated hepatic stellate cells (HSCs), the originators of liver fibrosis and cirrhosis, and activated pancreatic stellate cells (PSCs), the originators of pancreas fibrosis and pancreatitis, and can be effective to reduce or prevent further chronic fibrosis by simultaneously reducing multiple fibrosis-associated molecules secreted or induced by such activated stellate cells. The compositions are typically effective to target agonistic TRAIL receptors such as TRAIL-R1/DR4 and TRAIL-R2/DR5 that are selectively expressed in activated HSCs and PSCs in physiological conditions. Ligands and agonists that can be used to target agonistic TRAIL receptors include, but are not limited to, TRAIL-R1/DR4 and/or TRAIL-R2/DR5 agonists. | 2016-01-28 |
20160022777 | COMBINATION THERAPY WITH IL-12 - Pharmaceutical compositions and treatments involving iNKT cell activation are provided. | 2016-01-28 |
20160022778 | A METHOD FOR TREATING TUMOR BY USING RECOMBINANT INTERFERON WITH CHANGED SPATIAL CONFIGURATION - The present invention provides methods for treating tumors in subjects by using a recombinant interferon (rSIFN-co), and optionally, methods for treating solid tumors, such as lung cancer, among others, with or without prior surgery, and as a first line or second line monotherapy or in combination with one or more other anti-tumor therapies. The present invention further provides non-surgical methods for eliminating tumors or reducing tumor sizes in subjects, and/or preventing postoperative tumor recurrence and/or metastases in subjects by using the recombinant interferon (rSIFN-co) which comprises a unique spatial configuration, alone or in conjunction with radiotherapy, chemotherapy, and/or one or more anti-tumor drugs such as biological agents, targeted drugs, small molecules, Traditional Chinese Medicine (TCM) and the like. | 2016-01-28 |
20160022779 | ACTIVATORS OF CXCR3 FOR THE TREATMENT OF ANGIOPATHIES OF THE EYE - The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-γ-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal α-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof. | 2016-01-28 |
20160022780 | UROCORTIN 2 ANALOGS AND USES THEREOF - Disclosed are polypeptides that are analogs of urocortin 2 that have pharmacological activity similar to urocortin 2 but have improved water solubility compared to urocortin 2, and pharmaceutical compositions of the polypeptides of the present invention. Also disclosed are polynucleotides encoding the polypeptides, and methods of treating pathophysiological states employing pharmaceutical compositions of the polypeptides and polynucleotides of the present invention. In addition, disclosed are vectors and host cells that include a nucleic acid encoding a polypeptide of the present invention, and kits that include pharmaceutical compositions of the present invention. | 2016-01-28 |
20160022781 | METHODS FOR ADMINISTERING HYPOGLYCEMIC AGENTS - The present invention relates to methods of administering hypoglycemic agents and/or GLP-1 agonists. | 2016-01-28 |
20160022782 | INSULIN-CONTAINING INFANT FORMULA - The present invention provides compositions methods and kits for improved infant formula, particularly to insulin-supplements and formulae comprising same that mimic the diurnal rhythm and/or the postpartum variation of insulin in human milk. | 2016-01-28 |
20160022783 | POLYALKYLENE OXIDE VALERATE HEMOGLOBIN CONJUGATES - The present invention relates generally to polyethylene glycol (PEG) conjugated hemoglobins made by conjugation of succinimidyl-valerate activated polyethylene glycol to primary amines and N-terminal valines of the hemoglobin. | 2016-01-28 |
20160022784 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS - A process for inhibiting a mammalian cancerous cell or virally infected cell includes providing a | 2016-01-28 |
20160022785 | COMPOSITIONS AND METHODS FOR TREATING GLUTEN INTOLERANCE AND DISORDERS ARISING THEREFROM - The invention described herein relates to methods and compositions for treatment of gluten intolerance and related conditions (e.g., celiac disease and gluten sensitivity), or inhibition of inflammation and/or immune response in the intestine due to antigenic food peptides, by administration of a pharmaceutical composition comprising one or more | 2016-01-28 |
20160022786 | Anti-Cancer Combination Treatment and Kit-of-Parts - In one aspect the present invention relates to pharmaceutical kits of parts suitable for treating neoplastic diseases such as cancer comprising an anti-cancer medicament, a Basidiomycete bioactive agent in solid or liquid form, and, optionally instructions for a dosing regime. | 2016-01-28 |
20160022787 | Peptide Immunogens - The invention provides for the synthesis of more effective generators of a T-cell immune response by providing peptide derivatives that are MHC class I-restricted antigens. The peptide derivatives of the present invention are prepared or derived from a parent peptide of 8 to 11 amino acid residues in length, wherein the peptide derivative contains a non-natural amino acid substituted in place of a naturally-occurring amino acid residue at one or more primary anchor positions in the parent peptide or at position 6, position 7, or the C-terminus. | 2016-01-28 |
20160022788 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES - The present invention provides compositions comprising immunologically effective amounts of one or more autoimmune disease associated antigens or antigenic fragments or derivatives thereof and one or more Th2 promoting adjuvants. The compositions may optionally comprise one or more Th2 promoting TLR2 ligands. The invention further provides methods of treating or preventing an autoimmune disease, such as multiple sclerosis, comprising administering to a subject in need thereof an immunologically-effective amount of an autoimmune disease associated antigen, a Th2 promoting adjuvant and optionally one or more Th2 promoting TLR2 ligands which overall causes re-routing of the harming immune cells to places where they can be of no harm. | 2016-01-28 |
20160022789 | INDIVIDUALIZED HIGH PURITY COLON CARCINOMA STEM CELLS, METHODS AND USE OF THE SAME - The disclosure provides cancer stem cells, for use in stimulating immune response against a cancer, such as colon carcinoma (CC). Methods for preparing and purifying the cancer stem cells are provided. | 2016-01-28 |
20160022790 | VACCINE FOR THE PREVENTION OF BREAST CANCER RECURRENCE - Provided are methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, GP2, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission, including patients having low to intermediate levels of HER2/neu expression. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as GM-CSF, and the GP2 peptide. The methods may further comprise administering a periodic booster vaccine dose as needed due to declining GP2-specific T cell immunity. Also provided are vaccine compositions for use in the methods. | 2016-01-28 |
20160022791 | Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of Cancer - The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as lung carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against lung and other cancers. | 2016-01-28 |
20160022792 | ANTIGEN PRESENTING CELL TARGETED CANCER VACCINES - The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies. | 2016-01-28 |
20160022793 | COMPOSITIONS FOR TREATMENT AND/OR PREVENTION OF AUTOIMMUNE DISORDERS - The invention provides compositions for treating or preventing T1D (T1D), the compositions comprising one or more antigen presenting cells (APC) that have been pulsed with one or more bacteria and/or components of the bacteria, wherein the bacteria or their components confer upon the APCs the ability to inhibit the generation of diabetes-promoting T cells. The subject invention also provides a method of treating or preventing T1D in a subject, the method comprising administering APC that have been pulsed with one or more bacteria and/or components of the bacteria and wherein the bacteria or their components confer upon the APCs the ability to inhibit the generation of diabetes-promoting T cells. | 2016-01-28 |
20160022794 | SIDEROPHORE-BASED IMMUNIZATION AGAINST GRAM-NEGATIVE BACTERIA - The present invention provides novel enterobactin-carrier protein conjugates and salmochelin-carrier protein conjugates, such as compounds of Formula (I), and salts thereof. The present invention also provides compositions, kits, and methods that involve the compounds of Formula (I) and are useful in inducing an immune response, treating a bacterial infection and/or inflammatory bowel disease in a subject, preventing a bacterial infection and/or inflammatory bowel disease in a subject, or inhibiting the growth of or killing a bacterium. | 2016-01-28 |
20160022795 | Prevention and Treatment of Mycobacterium Infection - The invention relates to the identification of antigens, including | 2016-01-28 |
20160022796 | Synthetic Immunogens For Prophylaxis Or Treatment Of Tuberculosis - Compositions comprising a nucleic acid molecule that encodes TB esat-6 proteins are disclosed. Methods of inducing an immune response against TB an individual are disclosed. Method of treating an individual who has been diagnosed with TB are disclosed. Method of preventing TB infection in an individual are disclosed. | 2016-01-28 |
20160022797 | RAPID AND PROLONGED IMMUNOLOGIC-THERAPEUTIC - The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT). | 2016-01-28 |
20160022798 | COMPOSITIONS AND METHODS FOR PREPARING STAPHYLOCOCCUS AUREUS SEROTYPE 5 AND 8 CAPSULAR POLYSACCHARIDE CONJUGATE IMMUNOGENIC COMPOSITIONS - The present invention relates to immunogenic conjugates comprising | 2016-01-28 |
20160022799 | METHODS AND COMPOSITIONS EMPLOYING IMMUNOGENIC FUSION PROTEINS - Compositions and methods are provided for the prevention and treatment of bacterial infections, including pneumo-coccal infections. Compositions provided herein comprise a variety of immunogenic fusion proteins, wherein at least one poly-peptide component of a given fusion protein comprises a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof. Methods are provided for the prevention and treatment of bacterial infections, including pneumococcal infections by employing the various immunogenic fusion proteins having at least one polypeptide component comprising a CbpA polypeptide and/or a cytolysoid polypeptide, or an active variant or fragment thereof. | 2016-01-28 |
20160022800 | TRANSCUTANEOUS DOSAGE FORMULATION - Provided are topical delivery systems and methods for treating and/or preventing a disease or disorder in a subject, or for eliciting an immune response in a subject, including applying, to at least a portion of the subject's post-auricular region, a topical delivery system including a therapeutically effective amount of a topical pharmaceutical composition comprising at least one active agent and a pharmaceutically acceptable carrier and/or adjuvant. The topical pharmaceutical composition can include a topical immunogenic composition. The topical delivery system can further include a flexible substrate in communication with the topical immunogenic composition. The subject can be a pediatric subject. | 2016-01-28 |
20160022801 | RODENT HEPADNAVIRUS CORES WITH REDUCED CARRIER-SPECIFIC ANTIGENICITY - The present disclosure generally relates to hepadnavirus core antigens in which one or more endogenous b cell epitopes have been effectively removed. More specifically, the present disclosure relates to rodent hepadnavirus cores modified to diminish the antibody response to the core so as to enhance the antibody response to heterologous polypeptides included therein. | 2016-01-28 |
20160022802 | Novel Vaccines Against Multiple Subtypes Of Dengue Virus - An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide, such as a consensus dengue prME that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all 4 dengue subtypes. | 2016-01-28 |
20160022803 | VACCINE - The disclosure provides immunogenic compositions comprising human picornavirus peptides derived from structural proteins of the virus, constructs comprising the peptides, the peptides themselves and their use in the prevention of picornavirus infection and disease. Particular peptides from VP4 and VP1 are disclosed. | 2016-01-28 |
20160022804 | Immunogenic Human Rhinovirus (HRV) Compositions - Novel compositions useful as human rhino virus immunogens are provided. The compositions enable a host response to sites normally not recognized by a host. | 2016-01-28 |
20160022805 | COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR HUMAN AND AVIAN H5N1 INFLUENZA - Described herein is the generation of optimized H5N 1 influenza HA polypeptides for eliciting a broadly reactive immune response to H5N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on human and avian H5N1 isolates. Provided herein are optimized H5N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure. | 2016-01-28 |
20160022806 | Influenza Nucleic Acid Molecules And Vaccines Made Therefrom - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin and/or influenza B hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more influenza A serotypes and/or influenza B serotypes, or combinations thereof, using the vaccines that are provided. | 2016-01-28 |
20160022807 | METHODS AND COMPOSITIONS FOR IN VIVO IMMUNE STIMULATION AND ANTIGEN PRODUCTION - Disclosed are compositions and methods comprising a vector and a reverse genetics competent unit. The vector may comprise baculovirus expression vectors, bacmids, vaccinia virus and synthetic vectors and the reverse genetics competent unit may comprise pathogenic units necessary for producing pathogens de novo from a nucleotide-based vector. In certain embodiments, the reverse genetics competent unit comprises pathogenic units necessary for producing pathogens de novo from a nucleotide-based vector for influenza virus. | 2016-01-28 |
20160022808 | Method for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic Sendai virus - The invention relates to the field of immunology and medicine, more specifically, oncology, and can be useful for the treatment of patients with carcinomas and sarcomas. A pharmaceutical composition is provided which contains biologically active oncolytic Sendai virus strain Moscow PTA-13024, and a method of treating patients with said malignancies is developed including administration of the said composition to a patient's body. The strain Sendai-Moscow PTA-13024 is characterized by high oncolytic activity and safety for humans. The exploitation of the invention allows an increase in efficacy of treatment due to direct elimination of malignant cells via virus action and induction of anti-tumor immunity by viruses. | 2016-01-28 |
20160022809 | 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE - The present invention relates to novel 6-acetylmorphine analogs, and methods for their synthesis and use. Such analogs are designed to provide a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label. | 2016-01-28 |
20160022810 | Method for Treating Cancers by Alternating Immunotherapeutics and Directly Oncolytic Therapeutics - The present invention describes a unique immunotherapeutic method of treating cancer with the administration of CATS™ or an alternation of CATS™ immunotherapeutic followed by a directly oncolytic compound or agent, which protocol (BYES) can be by example an agent specifically targeting cancer stern cells, other cancer-specific growth pathways, radiotherapy, or compartmentalized chemotherapy. The BYES combination of CATS™ immunotherapeutic with cyclophosphamide delivers a very high statistical significant difference in survival and primary tumor control compared against either agent individually. | 2016-01-28 |
20160022811 | RITUXIMAB INDUCTION THERAPY FOLLOWED BY GLATIRAMER ACETATE THERAPY - The present invention provides a method of treating a subject afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome comprising periodic administration of an amount of an anti-CD20 antibody at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject, wherein the amounts are effective to treat the subject. | 2016-01-28 |
20160022812 | THERAPEUTIC AGENTS FOR PANCREATIC CANCER - We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an IL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated. | 2016-01-28 |
20160022813 | COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND CARFILZOMIB - Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and carfilzomib compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits. | 2016-01-28 |
20160022814 | COMBINATION OF A PD-1 ANTAGONIST AND A LISTERIA-BASED VACCINE FOR TREATING PROSTATE CANCER - The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a | 2016-01-28 |
20160022815 | Cures for Asthma, Psoriasis, Eczema, Epilepsy, Seizures, Soft Teeth, and Any Other Disease or Ailment Caused by Ascaris Parasites, Whether in Humans or Animals - A new method of exterminating or repelling certain disease- or malady-causing parasites in humans and animals using the radio frequencies of human immune system defense chemicals benzoquinone and/or rhodizonic acid superimposed upon small bottles of plain water which is then ingested by the human or animal. The radio frequencies of human immune system defense chemicals superimposed upon small bottles of plain water create facsimiles of those human immune system defense chemicals. | 2016-01-28 |
20160022816 | IDENTIFICATION OF SURGICAL SMOKE - A method includes assessing tumor margins and discriminating between tumor and non-tumor tissues by analyzing the compositional make-up of smoke produced during cautery resection of tissues. | 2016-01-28 |
20160022817 | Photoswitchable HDAC Inhibitors - This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same. Provided herein are inhibitors of HDAC having photoswitchable modulators of protein function with short thermal relaxation kinetics. The compounds are diazo compounds including a substituted or unsubstituted aryl or heteroaryl ring, wherein at least one of the rings is substituted with one or more HDAC targeting elements. | 2016-01-28 |
20160022818 | PHARMACEUTICAL FORMULATION COMPRISING LIPASE INHIBITOR HAVING INCREASED DISSOLUTION RATE AND REDUCED SIDE EFFECTS, AND METHOD FOR PREPARING SAME - The present invention provides a pharmaceutical formulation for increasing the dissolution rate of a lipase inhibitor and reducing side effects of the lipase inhibitor, including oily anal leakage, and a method for preparing the same, the pharmaceutical formulation comprising: a lipase inhibitor, and a porous adsorbent on which a thin film of the lipase inhibitor is formed. | 2016-01-28 |